68Ga-FF58

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Brain NeoplasmsGastroesophageal AdenocarcinomaGlioblastoma MultiformePancreatic Ductal Adenocarcinoma

Early Phase 1

Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.

TerminatedNCT04712721

Novartis PharmaceuticalsBrain Neoplasms, Gastroesophageal Adenocarcinoma, Glioblastoma Multiforme +1

Start: 2021-10-14End: 2024-07-01Updated: 2025-10-10

Phase 1

A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.

TerminatedNCT05977322

Novartis PharmaceuticalsGastroesophageal Adenocarcinoma, Glioblastoma Multiforme, Pancreatic Ductal Adenocarcinoma

Start: 2023-10-06End: 2024-12-13Updated: 2025-12-24